Skip to main content Accessibility help
×
Home
Hostname: page-component-568f69f84b-lkk24 Total loading time: 0.204 Render date: 2021-09-22T16:09:07.607Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Article contents

EPA-0719 – Post Hoc Analyses on the Efficacy of Lisdexamfetamine Dimesylate Following Previous Treatment with Attention Deficit/Hyperactivity Disorder Medication

Published online by Cambridge University Press:  15 April 2020

T. Banaschewski
Affiliation:
Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Mannheim, Germany
M. Lecendreux
Affiliation:
Paediatric Sleep Centre and National Reference Centre for Orphan Diseases: Narcolepsy Idiopathic Hypersomnia and Kleine-Levin Syndrome, Robert-Debré University Hospital, Paris, France
C. Soutullo
Affiliation:
Department of Psychiatry and Medical Psychology, University of Navarra, Pamplona, Spain
A. Zuddas
Affiliation:
Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy
S. Sorooshian
Affiliation:
Clinical Development and Medical Affairs, Shire AG, Eysins, Switzerland
B. Adeyi
Affiliation:
Global Biostatistics, Shire Development LLC, Wayne, USA
L.A. Squires
Affiliation:
Global Clinical Development and Innovation, Shire Development LLC, Wayne, USA
R. Civil
Affiliation:
Clinical Development and Medical Affairs, Shire Development LLC, Wayne, USA
D.R. Coghill
Affiliation:
Division of Neuroscience, University of Dundee, Dundee, United Kingdom
Get access

Abstract

Background:

The prodrug lisdexamfetamine dimesylate (LDX) is licensed in several European countries for treating attention-deficit/hyperactivity disorder (ADHD) in children and adolescents with an inadequate response to methylphenidate (MPH) treatment.

Objectives/Aims:

To evaluate post hoc the impact of ADHD medication history on the efficacy of LDX.

Methods:

In this 7-week, dose-optimized, double-blind, study, patients (6–17 years) were randomized 1:1:1 to LDX, placebo or osmotic-release oral system methylphenidate (OROS-MPH). Efficacy assessments included ADHD Rating Scale IV (ADHD-RS-IV) and Clinical Global Impressions-Improvement (CGI-I) scores.

Results:

The full analysis set (FAS) comprised 317 patients. Baseline characteristics were similar across treatment groups and previous treatment subgroups. At endpoint, the mean change from baseline in ADHD-RS-IV total score and proportions of responders based on a CGI-I of 1 or 2 for LDX, OROS-MPH and placebo are presented below.

Previous treatment sub-groupLDXPlaceboOROS-MPH
Mean change (SD) in ADHD-RS-IV total score
FAS (N=317)−24.7 (10.15)−6.3 (10.02)−18.9 (12.92)
Treatment-naïve (n=147)−24.0 (10.00)−8.5 (10.34)−21.4 (13.09)
Any previous ADHD medication (n=170)−25.3 (10.34)−4.2 (9.30)−16.9 (12.53)
Previous MPH treatment (n=146)−25.4 (10.67)−4.7 (9.70)−17.7 (11.96)
Proportion of responders (95% CI): CGI-I 1 or 2
FAS (N=317)78.0% (69.9, 86.1)14.4% (7.7, 21.2)60.6% (51.2, 70.0)
Treatment-naïve (n=147)80.4% (69.0, 91.9)19.6% (8.7, 30.5)63.8% (50.1, 77.6)
Any previous ADHD medication (n=170)75.9% (64.5, 87.3)9.4% (1.6, 17.3)57.9% (45.1, 70.7)

Conclusions:

LDX and OROS-MPH were associated with clinically relevant improvements in ADHD symptoms irrespective of ADHD medication history.

Study funded by Shire

Type
E06 - e-Poster Oral Session 06: Child Psychiatry and Personality Disorders
Copyright
Copyright © European Psychiatric Association 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

Comments

No Comments have been published for this article.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

EPA-0719 – Post Hoc Analyses on the Efficacy of Lisdexamfetamine Dimesylate Following Previous Treatment with Attention Deficit/Hyperactivity Disorder Medication
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

EPA-0719 – Post Hoc Analyses on the Efficacy of Lisdexamfetamine Dimesylate Following Previous Treatment with Attention Deficit/Hyperactivity Disorder Medication
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

EPA-0719 – Post Hoc Analyses on the Efficacy of Lisdexamfetamine Dimesylate Following Previous Treatment with Attention Deficit/Hyperactivity Disorder Medication
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *